TD Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

TD Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,383	Closed	-$629K	–	1515
2021 Q1	$629K	Buy	6,383 +1,283	+25%	+$154K	﹤0.01%	1360
2020 Q4	$553K	Buy	5,100 +750	+17%	+$92.8K	﹤0.01%	1315
2020 Q3	$448K	Sell	4,350 -3,000	-41%	-$449K	﹤0.01%	1266
2020 Q2	$1.53M	Buy	7,350 +96	+1%	+$17K	﹤0.01%	945
2020 Q1	$709K	Buy	7,254 +1,599	+28%	+$186K	﹤0.01%	1089
2019 Q4	$651K	Sell	5,655 -370	-6%	-$32.6K	﹤0.01%	1192
2019 Q3	$328K	Buy	6,025 +4,565	+313%	+$514K	﹤0.01%	1239
2019 Q2	$174K	Buy	+1,460	New	+$121K	﹤0.01%	1306
2015 Q2	–	Sell	-2,434	Closed	-$986K	–	1397
2015 Q1	$986K	Buy	2,434 +1,684	+225%	+$712K	﹤0.01%	945
2014 Q4	$405K	Hold	750	–	–	﹤0.01%	1151
2014 Q3	$256K	Buy	+750	New	+$223K	﹤0.01%	1191

Other funds holding ADVM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TD Asset Management's ADVM Position: Q2 2021 in Review

TD Asset Management sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 6,383 shares — an estimated $629K sold.

TD Asset Management first reported a position in ADVM in Q3 2014 and held it in 11 quarters. The position peaked at $1.53M in Q2 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

TD Asset Management reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
TD Asset Management sold 6,383 Adverum Biotechnologies shares in Q2 2021, an estimated $629K.
TD Asset Management first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 11 quarters.
TD Asset Management's Adverum Biotechnologies position peaked at $1.53M in Q2 2020.
118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on TD Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.